Heidel FH - Search Results

1

Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms.

Jayavelu AK, Schnöder TM, Perner F, Herzog C, Meiler A, Krishnamoorthy G, Huber N, Mohr J, Edelmann-Stephan B, Austin R, Brandt S, Palandri F, Schröder N, Isermann B, Edlich F, Sinha AU, Ungelenk M, Hübner CA, Zeiser R, Rahmig S, Waskow C, Coldham I, Ernst T, Hochhaus A, Jilg S, Jost PJ, Mullally A, Bullinger L, Mertens PR, Lane SW, Mann M, Heidel FH. Jayavelu AK, et al. Among authors: heidel fh. Nature. 2020 Dec;588(7836):157-163. doi: 10.1038/s41586-020-2968-3. Epub 2020 Nov 25. Nature. 2020. PMID: 33239784

2

Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera-Advanced Integrated Models (PV-AIM) Project.

Verstovsek S, Krečak I, Heidel FH, De Stefano V, Bryan K, Zuurman MW, Zaiac M, Morelli M, Smyth A, Redondo S, Bigan E, Ruhl M, Meier C, Beffy M, Kiladjian JJ. Verstovsek S, et al. Among authors: heidel fh. Biomedicines. 2023 Jul 7;11(7):1925. doi: 10.3390/biomedicines11071925. Biomedicines. 2023. PMID: 37509564 Free PMC article.

3

Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.

Zirm E, Spies-Weisshart B, Heidel F, Schnetzke U, Böhmer FD, Hochhaus A, Fischer T, Scholl S. Zirm E, et al. Br J Haematol. 2012 May;157(4):483-92. doi: 10.1111/j.1365-2141.2012.09085.x. Epub 2012 Mar 13. Br J Haematol. 2012. PMID: 22409268

4

Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML.

Heidel FH, Bullinger L, Feng Z, Wang Z, Neff TA, Stein L, Kalaitzidis D, Lane SW, Armstrong SA. Heidel FH, et al. Cell Stem Cell. 2012 Apr 6;10(4):412-24. doi: 10.1016/j.stem.2012.02.017. Cell Stem Cell. 2012. PMID: 22482506 Free PMC article.

5

Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.

Lipka DB, Wagner MC, Dziadosz M, Schnöder T, Heidel F, Schemionek M, Melo JV, Kindler T, Müller-Tidow C, Koschmieder S, Fischer T. Lipka DB, et al. PLoS One. 2012;7(7):e40853. doi: 10.1371/journal.pone.0040853. Epub 2012 Jul 16. PLoS One. 2012. PMID: 22815843 Free PMC article.

6

The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML.

Heidel FH, Bullinger L, Arreba-Tutusaus P, Wang Z, Gaebel J, Hirt C, Niederwieser D, Lane SW, Döhner K, Vasioukhin V, Fischer T, Armstrong SA. Heidel FH, et al. J Exp Med. 2013 Jan 14;210(1):15-22. doi: 10.1084/jem.20120596. Epub 2012 Dec 31. J Exp Med. 2013. PMID: 23277453 Free PMC article.

7

Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.

Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, Austin R, Heckl D, Breyfogle LJ, Kuhn CP, Kalaitzidis D, Armstrong SA, Williams DA, Hill GR, Ebert BL, Lane SW. Mullally A, et al. Among authors: heidel fh. Blood. 2013 May 2;121(18):3692-702. doi: 10.1182/blood-2012-05-432989. Epub 2013 Mar 13. Blood. 2013. PMID: 23487027 Free PMC article.

8

Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.

Wolleschak D, Mack TS, Perner F, Frey S, Schnöder TM, Wagner MC, Höding C, Pils MC, Parkner A, Kliche S, Schraven B, Hebel K, Brunner-Weinzierl M, Ranjan S, Isermann B, Lipka DB, Fischer T, Heidel FH. Wolleschak D, et al. Among authors: heidel fh. Haematologica. 2014 Jun;99(6):e90-3. doi: 10.3324/haematol.2014.104331. Epub 2014 Mar 14. Haematologica. 2014. PMID: 24633870 Free PMC article. No abstract available.

9

Epo-induced erythroid maturation is dependent on Plcγ1 signaling.

Schnöder TM, Arreba-Tutusaus P, Griehl I, Bullinger L, Buschbeck M, Lane SW, Döhner K, Plass C, Lipka DB, Heidel FH, Fischer T. Schnöder TM, et al. Among authors: heidel fh. Cell Death Differ. 2015 Jun;22(6):974-85. doi: 10.1038/cdd.2014.186. Epub 2014 Nov 14. Cell Death Differ. 2015. PMID: 25394487 Free PMC article.

10

Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy.

Bruedigam C, Bagger FO, Heidel FH, Paine Kuhn C, Guignes S, Song A, Austin R, Vu T, Lee E, Riyat S, Moore AS, Lock RB, Bullinger L, Hill GR, Armstrong SA, Williams DA, Lane SW. Bruedigam C, et al. Among authors: heidel fh. Cell Stem Cell. 2014 Dec 4;15(6):775-90. doi: 10.1016/j.stem.2014.11.010. Cell Stem Cell. 2014. PMID: 25479751 Free PMC article.

11

Defective podocyte insulin signalling through p85-XBP1 promotes ATF6-dependent maladaptive ER-stress response in diabetic nephropathy.

Madhusudhan T, Wang H, Dong W, Ghosh S, Bock F, Thangapandi VR, Ranjan S, Wolter J, Kohli S, Shahzad K, Heidel F, Krueger M, Schwenger V, Moeller MJ, Kalinski T, Reiser J, Chavakis T, Isermann B. Madhusudhan T, et al. Nat Commun. 2015 Mar 10;6:6496. doi: 10.1038/ncomms7496. Nat Commun. 2015. PMID: 25754093 Free PMC article.

12

Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function.

Perner F, Schnöder TM, Ranjan S, Wolleschak D, Ebert C, Pils MC, Frey S, Polanetzki A, Fahldieck C, Schönborn U, Schraven B, Isermann B, Fischer T, Heidel FH. Perner F, et al. Among authors: heidel fh. Leukemia. 2016 Apr;30(4):991-5. doi: 10.1038/leu.2015.218. Epub 2015 Aug 5. Leukemia. 2016. PMID: 26242463 No abstract available.

13

Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo.

Arreba-Tutusaus P, Mack TS, Bullinger L, Schnöder TM, Polanetzki A, Weinert S, Ballaschk A, Wang Z, Deshpande AJ, Armstrong SA, Döhner K, Fischer T, Heidel FH. Arreba-Tutusaus P, et al. Among authors: heidel fh. Leukemia. 2016 May;30(5):1220-1225. doi: 10.1038/leu.2015.292. Epub 2015 Oct 21. Leukemia. 2016. PMID: 26487272 Free PMC article. No abstract available.

14

Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo.

Ebert C, Perner F, Wolleschak D, Schnöder TM, Fischer T, Heidel FH. Ebert C, et al. Among authors: heidel fh. Haematologica. 2016 Mar;101(3):e81-5. doi: 10.3324/haematol.2015.136754. Epub 2015 Nov 20. Haematologica. 2016. PMID: 26589910 Free PMC article. No abstract available.

15

Kinomics Screening Identifies Aberrant Phosphorylation of CDC25C in FLT3-ITD-positive AML.

Perner F, Schnöder TM, Fischer T, Heidel FH. Perner F, et al. Among authors: heidel fh. Anticancer Res. 2016 Dec;36(12):6249-6258. doi: 10.21873/anticanres.11219. Anticancer Res. 2016. PMID: 27919943

16

RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts.

Gieseler-Halbach S, Meltendorf S, Pierau M, Weinert S, Heidel FH, Fischer T, Handschuh J, Braun-Dullaeus RC, Schrappe M, Lindquist JA, Mertens PR, Thomas U, Brunner-Weinzierl MC. Gieseler-Halbach S, et al. Among authors: heidel fh. Cell Death Differ. 2017 Feb;24(2):371-383. doi: 10.1038/cdd.2016.141. Epub 2016 Dec 23. Cell Death Differ. 2017. PMID: 28009354 Free PMC article.

17

Gain of function in Jak2^V617F-positive T-cells.

Nishanth G, Wolleschak D, Fahldieck C, Fischer T, Mullally A, Perner F, Schnöder TM, Just S, Heidel FH, Schlüter D. Nishanth G, et al. Among authors: heidel fh. Leukemia. 2017 Apr;31(4):1000-1003. doi: 10.1038/leu.2017.6. Epub 2017 Jan 11. Leukemia. 2017. PMID: 28074070 No abstract available.

18

Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.

Schnöder TM, Eberhardt J, Koehler M, Bierhoff HB, Weinert S, Pandey AD, Nimmagadda SC, Wolleschak D, Jöhrens K, Fischer T, Heidel FH. Schnöder TM, et al. Among authors: heidel fh. J Cancer Res Clin Oncol. 2017 May;143(5):807-820. doi: 10.1007/s00432-017-2354-1. Epub 2017 Feb 23. J Cancer Res Clin Oncol. 2017. PMID: 28233092

19

Mitochondrial BAX Determines the Predisposition to Apoptosis in Human AML.

Reichenbach F, Wiedenmann C, Schalk E, Becker D, Funk K, Scholz-Kreisel P, Todt F, Wolleschak D, Döhner K, Marquardt JU, Heidel F, Edlich F. Reichenbach F, et al. Clin Cancer Res. 2017 Aug 15;23(16):4805-4816. doi: 10.1158/1078-0432.CCR-16-1941. Epub 2017 Apr 18. Clin Cancer Res. 2017. PMID: 28420723

20

Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation.

Tsitsipatis D, Jayavelu AK, Müller JP, Bauer R, Schmidt-Arras D, Mahboobi S, Schnöder TM, Heidel F, Böhmer FD. Tsitsipatis D, et al. Oncotarget. 2017 Apr 18;8(16):26613-26624. doi: 10.18632/oncotarget.15772. Oncotarget. 2017. PMID: 28460451 Free PMC article.

21

Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells.

Ranjan S, Goihl A, Kohli S, Gadi I, Pierau M, Shahzad K, Gupta D, Bock F, Wang H, Shaikh H, Kähne T, Reinhold D, Bank U, Zenclussen AC, Niemz J, Schnöder TM, Brunner-Weinzierl M, Fischer T, Kalinski T, Schraven B, Luft T, Huehn J, Naumann M, Heidel FH, Isermann B. Ranjan S, et al. Among authors: heidel fh. Nat Commun. 2017 Aug 21;8(1):311. doi: 10.1038/s41467-017-00169-4. Nat Commun. 2017. PMID: 28827518 Free PMC article.

22

Protein phosphatase 4 regulatory subunit 2 (PPP4R2) is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair.

Herzig JK, Bullinger L, Tasdogan A, Zimmermann P, Schlegel M, Teleanu V, Weber D, Rücker FG, Paschka P, Dolnik A, Schneider E, Kuchenbauer F, Heidel FH, Buske C, Döhner H, Döhner K, Gaidzik VI. Herzig JK, et al. Among authors: heidel fh. Oncotarget. 2017 Sep 21;8(56):95038-95053. doi: 10.18632/oncotarget.21119. eCollection 2017 Nov 10. Oncotarget. 2017. PMID: 29221109 Free PMC article.

23

The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function.

Mohr J, Dash BP, Schnoeder TM, Wolleschak D, Herzog C, Tubio Santamaria N, Weinert S, Godavarthy S, Zanetti C, Naumann M, Hartleben B, Huber TB, Krause DS, Kähne T, Bullinger L, Heidel FH. Mohr J, et al. Among authors: heidel fh. Leukemia. 2018 May;32(5):1211-1221. doi: 10.1038/s41375-018-0025-0. Epub 2018 Jan 30. Leukemia. 2018. PMID: 29467485

24

Managing myeloproliferative neoplasms evidence based on the ELN treatment recommendations 2018.

Heidel FH, Gale RP, Hochhaus A. Heidel FH, et al. Leukemia. 2018 May;32(5):1055-1056. doi: 10.1038/s41375-018-0079-z. Epub 2018 Feb 27. Leukemia. 2018. PMID: 29515237 No abstract available.

25

Dysregulation of chemokine receptor expression and function in leukocytes from ALS patients.

Perner C, Perner F, Stubendorff B, Förster M, Witte OW, Heidel FH, Prell T, Grosskreutz J. Perner C, et al. Among authors: heidel fh. J Neuroinflammation. 2018 Mar 28;15(1):99. doi: 10.1186/s12974-018-1135-3. J Neuroinflammation. 2018. PMID: 29592817 Free PMC article.

26

Loss of DEP-1 (Ptprj) promotes myeloproliferative disease in FLT3-ITD acute myeloid leukemia.

Kresinsky A, Bauer R, Schnöder TM, Berg T, Meyer D, Ast V, König R, Serve H, Heidel FH, Böhmer FD, Müller JP. Kresinsky A, et al. Among authors: heidel fh. Haematologica. 2018 Nov;103(11):e505-e509. doi: 10.3324/haematol.2017.185306. Epub 2018 Jun 7. Haematologica. 2018. PMID: 29880609 Free PMC article. No abstract available.

27

JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation.

Edelmann B, Gupta N, Schnoeder TM, Oelschlegel AM, Shahzad K, Goldschmidt J, Philipsen L, Weinert S, Ghosh A, Saalfeld FC, Nimmagadda SC, Müller P, Braun-Dullaeus R, Mohr J, Wolleschak D, Kliche S, Amthauer H, Heidel FH, Schraven B, Isermann B, Müller AJ, Fischer T. Edelmann B, et al. Among authors: heidel fh. J Clin Invest. 2018 Oct 1;128(10):4359-4371. doi: 10.1172/JCI90312. Epub 2018 Jul 19. J Clin Invest. 2018. PMID: 30024857 Free PMC article.

28

Diverging impact of cell fate determinants Scrib and Llgl1 on adhesion and migration of hematopoietic stem cells.

Dash BP, Schnöder TM, Kathner C, Mohr J, Weinert S, Herzog C, Godavarthy PS, Zanetti C, Perner F, Braun-Dullaeus R, Hartleben B, Huber TB, Walz G, Naumann M, Ellis S, Vasioukhin V, Kähne T, Krause DS, Heidel FH. Dash BP, et al. Among authors: heidel fh. J Cancer Res Clin Oncol. 2018 Oct;144(10):1933-1944. doi: 10.1007/s00432-018-2724-3. Epub 2018 Aug 6. J Cancer Res Clin Oncol. 2018. PMID: 30083817

29

Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of K_v1.3 potassium channels, AKT and ERK1/2 signaling.

Lowinus T, Heidel FH, Bose T, Nimmagadda SC, Schnöder T, Cammann C, Schmitz I, Seifert U, Fischer T, Schraven B, Bommhardt U. Lowinus T, et al. Among authors: heidel fh. Cell Commun Signal. 2019 Jan 16;17(1):5. doi: 10.1186/s12964-018-0317-z. Cell Commun Signal. 2019. PMID: 30651113 Free PMC article.

30

Lack of CD45 in FLT3-ITD mice results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation.

Kresinsky A, Schnöder TM, Jacobsen ID, Rauner M, Hofbauer LC, Ast V, König R, Hoffmann B, Svensson CM, Figge MT, Hilger I, Heidel FH, Böhmer FD, Müller JP. Kresinsky A, et al. Among authors: heidel fh. Oncogene. 2019 Jun;38(24):4773-4787. doi: 10.1038/s41388-019-0757-y. Epub 2019 Feb 28. Oncogene. 2019. PMID: 30820040

31

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation.

Cocciardi S, Dolnik A, Kapp-Schwoerer S, Rücker FG, Lux S, Blätte TJ, Skambraks S, Krönke J, Heidel FH, Schnöder TM, Corbacioglu A, Gaidzik VI, Paschka P, Teleanu V, Göhring G, Thol F, Heuser M, Ganser A, Weber D, Sträng E, Kestler HA, Döhner H, Bullinger L, Döhner K. Cocciardi S, et al. Among authors: heidel fh. Nat Commun. 2019 May 2;10(1):2031. doi: 10.1038/s41467-019-09745-2. Nat Commun. 2019. PMID: 31048683 Free PMC article.

32

Plasma VCAM1 levels correlate with disease severity in Parkinson's disease.

Perner C, Perner F, Gaur N, Zimmermann S, Witte OW, Heidel FH, Grosskreutz J, Prell T. Perner C, et al. Among authors: heidel fh. J Neuroinflammation. 2019 May 8;16(1):94. doi: 10.1186/s12974-019-1482-8. J Neuroinflammation. 2019. PMID: 31068198 Free PMC article.

33

Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation.

Perner F, Perner C, Ernst T, Heidel FH. Perner F, et al. Among authors: heidel fh. Cells. 2019 Aug 8;8(8):854. doi: 10.3390/cells8080854. Cells. 2019. PMID: 31398915 Free PMC article. Review.

34

The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML.

Kahl M, Brioli A, Bens M, Perner F, Kresinsky A, Schnetzke U, Hinze A, Sbirkov Y, Stengel S, Simonetti G, Martinelli G, Petrie K, Zelent A, Böhmer FD, Groth M, Ernst T, Heidel FH, Scholl S, Hochhaus A, Schenk T. Kahl M, et al. Among authors: heidel fh. Leukemia. 2019 Nov;33(11):2628-2639. doi: 10.1038/s41375-019-0581-y. Epub 2019 Oct 1. Leukemia. 2019. PMID: 31576004

35

Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.

Austin RJ, Straube J, Bruedigam C, Pali G, Jacquelin S, Vu T, Green J, Gräsel J, Lansink L, Cooper L, Lee SJ, Chen NT, Lee CW, Haque A, Heidel FH, D'Andrea R, Hill GR, Mullally A, Milsom MD, Bywater M, Lane SW. Austin RJ, et al. Among authors: heidel fh. Leukemia. 2020 Apr;34(4):1075-1089. doi: 10.1038/s41375-019-0638-y. Epub 2019 Nov 15. Leukemia. 2020. PMID: 31732720 Free PMC article.

36

SHP1 regulates a STAT6-ITGB3 axis in FLT3ITD-positive AML cells.

Reich D, Kresinsky A, Müller JP, Bauer R, Kallenbach J, Schnoeder TM, Heidel FH, Fässler R, Mann M, Böhmer FD, Jayavelu AK. Reich D, et al. Among authors: heidel fh. Leukemia. 2020 May;34(5):1444-1449. doi: 10.1038/s41375-019-0676-5. Epub 2019 Dec 13. Leukemia. 2020. PMID: 31836852 No abstract available.

37

Correction: The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML.

Kahl M, Brioli A, Bens M, Perner F, Kresinsky A, Schnetzke U, Hinze A, Sbirkov Y, Stengel S, Simonetti G, Martinelli G, Petrie K, Zelent A, Böhmer FD, Groth M, Ernst T, Heidel FH, Scholl S, Hochhaus A, Schenk T. Kahl M, et al. Among authors: heidel fh. Leukemia. 2020 Jul;34(7):1972. doi: 10.1038/s41375-020-0706-3. Leukemia. 2020. PMID: 31949266

38

SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders.

Kaiser A, Schmidt M, Huber O, Frietsch JJ, Scholl S, Heidel FH, Hochhaus A, Müller JP, Ernst T. Kaiser A, et al. Among authors: heidel fh. Leukemia. 2020 Aug;34(8):2206-2216. doi: 10.1038/s41375-020-0803-3. Epub 2020 Mar 25. Leukemia. 2020. PMID: 32214204 Free PMC article.

39

Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders.

Midic D, Rinke J, Perner F, Müller V, Hinze A, Pester F, Landschulze J, Ernst J, Gruhn B, Matziolis G, Heidel FH, Hochhaus A, Ernst T. Midic D, et al. Among authors: heidel fh. Leukemia. 2020 Aug;34(8):2198-2205. doi: 10.1038/s41375-020-0869-y. Epub 2020 May 26. Leukemia. 2020. PMID: 32457355 Free PMC article.

40

Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study.

Crodel CC, Jentsch-Ullrich K, Koschmieder S, Kämpfe D, Griesshammer M, Döhner K, Jost PJ, Wolleschak D, Isfort S, Stegelmann F, Jilg S, Hofmann V, Auteri G, Rachow T, Ernst P, Brioli A, von Lilienfeld-Toal M, Hochhaus A, Palandri F, Heidel FH. Crodel CC, et al. Among authors: heidel fh. Leukemia. 2020 Jul;34(7):1949-1953. doi: 10.1038/s41375-020-0890-1. Epub 2020 May 30. Leukemia. 2020. PMID: 32474573 Free PMC article. No abstract available.

41

Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.

Heidel F, Hochhaus A. Heidel F, et al. Leukemia. 2020 Jul;34(7):1723-1725. doi: 10.1038/s41375-020-0898-6. Epub 2020 Jun 11. Leukemia. 2020. PMID: 32528040 Free PMC article. No abstract available.

42

Hematopoietic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukemia.

Vu T, Straube J, Porter AH, Bywater M, Song A, Ling V, Cooper L, Pali G, Bruedigam C, Jacquelin S, Green J, Magor G, Perkins A, Chalk AM, Walkley CR, Heidel FH, Mukhopadhyay P, Cloonan N, Gröschel S, Mallm JP, Fröhling S, Scholl C, Lane SW. Vu T, et al. Among authors: heidel fh. Nat Commun. 2020 Jun 15;11(1):3021. doi: 10.1038/s41467-020-16840-2. Nat Commun. 2020. PMID: 32541670 Free PMC article.

43

Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study.

Crodel CC, Jentsch-Ullrich K, Koschmieder S, Kämpfe D, Griesshammer M, Döhner K, Jost PJ, Wolleschak D, Isfort S, Stegelmann F, Jilg S, Hofmann V, Auteri G, Rachow T, Ernst P, Brioli A, von Lilienfeld-Toal M, Hochhaus A, Palandri F, Heidel FH. Crodel CC, et al. Among authors: heidel fh. Leukemia. 2020 Nov;34(11):3106. doi: 10.1038/s41375-020-0970-2. Leukemia. 2020. PMID: 32651539 Free PMC article.

44

Fibrosis and Immune Cell Infiltration Are Separate Events Regulated by Cell-Specific Receptor Notch3 Expression.

Brandt S, Ballhause TM, Bernhardt A, Becker A, Salaru D, Le-Deffge HM, Fehr A, Fu Y, Philipsen L, Djudjaj S, Müller AJ, Kramann R, Ibrahim M, Geffers R, Siebel C, Isermann B, Heidel FH, Lindquist JA, Mertens PR. Brandt S, et al. Among authors: heidel fh. J Am Soc Nephrol. 2020 Nov;31(11):2589-2608. doi: 10.1681/ASN.2019121289. Epub 2020 Aug 28. J Am Soc Nephrol. 2020. PMID: 32859670 Free PMC article.

45

PLCγ1 suppression promotes the adaptation of KRAS-mutant lung adenocarcinomas to hypoxia.

Saliakoura M, Rossi Sebastiano M, Pozzato C, Heidel FH, Schnöder TM, Savic Prince S, Bubendorf L, Pinton P, A Schmid R, Baumgartner J, Freigang S, Berezowska SA, Rimessi A, Konstantinidou G. Saliakoura M, et al. Among authors: heidel fh. Nat Cell Biol. 2020 Nov;22(11):1382-1395. doi: 10.1038/s41556-020-00592-8. Epub 2020 Oct 19. Nat Cell Biol. 2020. PMID: 33077911 Free PMC article.

46

A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs.

Schnoeder TM, Perner F, Heidel FH. Schnoeder TM, et al. Among authors: heidel fh. Mol Cell Oncol. 2021 Jan 30;8(2):1871172. doi: 10.1080/23723556.2020.1871172. Mol Cell Oncol. 2021. PMID: 33855167 Free PMC article.

47

YBX1 mediates translation of oncogenic transcripts to control cell competition in AML.

Perner F, Schnoeder TM, Xiong Y, Jayavelu AK, Mashamba N, Santamaria NT, Huber N, Todorova K, Hatton C, Perner B, Eifert T, Murphy C, Hartmann M, Hoell JI, Schröder N, Brandt S, Hochhaus A, Mertens PR, Mann M, Armstrong SA, Mandinova A, Heidel FH. Perner F, et al. Among authors: heidel fh. Leukemia. 2022 Feb;36(2):426-437. doi: 10.1038/s41375-021-01393-0. Epub 2021 Aug 31. Leukemia. 2022. PMID: 34465866 Free PMC article.

48

PLCG1 is required for AML1-ETO leukemia stem cell self-renewal.

Schnoeder TM, Schwarzer A, Jayavelu AK, Hsu CJ, Kirkpatrick J, Döhner K, Perner F, Eifert T, Huber N, Arreba-Tutusaus P, Dolnik A, Assi SA, Nafria M, Jiang L, Dai YT, Chen Z, Chen SJ, Kellaway SG, Ptasinska A, Ng ES, Stanley EG, Elefanty AG, Buschbeck M, Bierhoff H, Brodt S, Matziolis G, Fischer KD, Hochhaus A, Chen CW, Heidenreich O, Mann M, Lane SW, Bullinger L, Ori A, von Eyss B, Bonifer C, Heidel FH. Schnoeder TM, et al. Among authors: heidel fh. Blood. 2022 Feb 17;139(7):1080-1097. doi: 10.1182/blood.2021012778. Blood. 2022. PMID: 34695195 Free PMC article.

49

Publisher Correction: SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders.

Kaiser A, Schmidt M, Huber O, Frietsch JJ, Scholl S, Heidel FH, Hochhaus A, Müller JP, Ernst T. Kaiser A, et al. Among authors: heidel fh. Leukemia. 2021 Dec;35(12):3632. doi: 10.1038/s41375-021-01365-4. Leukemia. 2021. PMID: 34785796 Free PMC article. No abstract available.

50

Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera.

Crodel CC, Jentsch-Ullrich K, Reiser M, Jacobasch L, Sauer A, Tesch H, Ulshöfer T, Wunschel R, Palandri F, Heidel FH. Crodel CC, et al. Among authors: heidel fh. J Cancer Res Clin Oncol. 2022 Oct;148(10):2693-2705. doi: 10.1007/s00432-021-03855-5. Epub 2021 Nov 22. J Cancer Res Clin Oncol. 2022. PMID: 34807311 Free PMC article.

51

Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance.

Fleischmann M, Fischer M, Schnetzke U, Fortner C, Kirkpatrick J, Heidel FH, Hochhaus A, Scholl S. Fleischmann M, et al. Among authors: heidel fh. Cells. 2021 Nov 3;10(11):2992. doi: 10.3390/cells10112992. Cells. 2021. PMID: 34831215 Free PMC article.

52

Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms.

Ernst P, Schnöder TM, Huber N, Perner F, Jayavelu AK, Eifert T, Hsu CJ, Tubío-Santamaría N, Crodel CC, Ungelenk M, Hübner CA, Clement JH, Hochhaus A, Heidel FH. Ernst P, et al. Among authors: heidel fh. Leukemia. 2022 Jul;36(7):1843-1849. doi: 10.1038/s41375-022-01611-3. Epub 2022 Jun 2. Leukemia. 2022. PMID: 35654819 Free PMC article.

53

Pomalidomide combinations are a safe and effective option after daratumumab failure.

Brioli A, Gengenbach L, Mancuso K, Binder M, Ernst T, Heidel FH, Stauch T, Zamagni E, Hilgendorf I, Hochhaus A, Engelhardt M, von Lilienfeld-Toal M. Brioli A, et al. Among authors: heidel fh. J Cancer Res Clin Oncol. 2023 Aug;149(9):6569-6574. doi: 10.1007/s00432-023-04637-x. Epub 2023 Feb 13. J Cancer Res Clin Oncol. 2023. PMID: 36781500 Free PMC article.

54

Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia.

Eifert T, Hsu CJ, Becker AL, Graessle S, Horne A, Bemmann F, Zhang Q, Heuser M, Vasioukhin V, Scholl S, Hochhaus A, Siegerist F, Endlich N, Bullinger L, Lane SW, Haas S, Schnoeder TM, Heidel FH. Eifert T, et al. Among authors: heidel fh. Leukemia. 2023 Oct;37(10):2027-2035. doi: 10.1038/s41375-023-02005-9. Epub 2023 Aug 16. Leukemia. 2023. PMID: 37587260 Free PMC article.

55

Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia.

Tubío-Santamaría N, Jayavelu AK, Schnoeder TM, Eifert T, Hsu CJ, Perner F, Zhang Q, Wenge DV, Hansen FM, Kirkpatrick JM, Jyotsana N, Lane SW, von Eyss B, Deshpande AJ, Kühn MWM, Schwaller J, Cammann C, Seifert U, Ebstein F, Krüger E, Hochhaus A, Heuser M, Ori A, Mann M, Armstrong SA, Heidel FH. Tubío-Santamaría N, et al. Among authors: heidel fh. Mol Cancer. 2023 Dec 4;22(1):196. doi: 10.1186/s12943-023-01907-7. Mol Cancer. 2023. PMID: 38049829 Free PMC article.

56

FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN).

Isfort S, von Bubnoff N, Al-Ali HK, Becker H, Götze T, le Coutre P, Griesshammer M, Moskwa C, Wohn L, Riedel J, Palandri F, Manz K, Hochhaus A, Döhner K, Heidel FH. Isfort S, et al. Among authors: heidel fh. Ann Hematol. 2024 Aug;103(8):2775-2785. doi: 10.1007/s00277-024-05867-w. Epub 2024 Jul 5. Ann Hematol. 2024. PMID: 38967662 Free PMC article.

57

Immunofluorescence microscopy on the blood smear identifies patients with myeloproliferative neoplasms.

Zaninetti C, Vater L, Kaderali L, Crodel CC, Schnöder TM, Fuhrmann J, Swensson L, Wesche J, Freyer C, Greinacher A, Heidel FH. Zaninetti C, et al. Among authors: heidel fh. Leukemia. 2024 Sep;38(9):2051-2058. doi: 10.1038/s41375-024-02346-z. Epub 2024 Jul 17. Leukemia. 2024. PMID: 39020061 Free PMC article. No abstract available.

58

Malignant JAK-signaling: at the interface of inflammation and malignant transformation.

Perner F, Pahl HL, Zeiser R, Heidel FH. Perner F, et al. Among authors: heidel fh. Leukemia. 2025 May;39(5):1011-1030. doi: 10.1038/s41375-025-02569-8. Epub 2025 Mar 26. Leukemia. 2025. PMID: 40140631 Free PMC article. Review.

59

[Development of tyrosine kinase inhibitors for hematologic neoplasms. FLT3 and JAK2 as therapeutic targets].

Lipka D, Heidel F, Huber C, Fischer T. Lipka D, et al. Pharm Unserer Zeit. 2008;37(5):394-403. doi: 10.1002/pauz.200800280. Pharm Unserer Zeit. 2008. PMID: 18729264 Review. German. No abstract available.

60

Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro.

Heidel F, Lipka DB, Mirea FK, Mahboobi S, Grundler R, Kancha RK, Duyster J, Naumann M, Huber C, Böhmer FD, Fischer T. Heidel F, et al. Br J Haematol. 2009 Mar;144(6):865-74. doi: 10.1111/j.1365-2141.2008.07567.x. Epub 2009 Jan 16. Br J Haematol. 2009. PMID: 19183186

61

3,4-Diarylmaleimides-a novel class of kinase inhibitors-effectively induce apoptosis in FLT3-ITD-dependent cells.

Heidel FH, Mack TS, Razumovskaya E, Blum MC, Lipka DB, Ballaschk A, Kramb JP, Plutizki S, Rönnstrand L, Dannhardt G, Fischer T. Heidel FH, et al. Ann Hematol. 2012 Mar;91(3):331-44. doi: 10.1007/s00277-011-1311-3. Epub 2011 Sep 1. Ann Hematol. 2012. PMID: 21881825

62

NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells.

Jayavelu AK, Müller JP, Bauer R, Böhmer SA, Lässig J, Cerny-Reiterer S, Sperr WR, Valent P, Maurer B, Moriggl R, Schröder K, Shah AM, Fischer M, Scholl S, Barth J, Oellerich T, Berg T, Serve H, Frey S, Fischer T, Heidel FH, Böhmer FD. Jayavelu AK, et al. Among authors: heidel fh. Leukemia. 2016 Feb;30(2):473-83. doi: 10.1038/leu.2015.234. Epub 2015 Aug 26. Leukemia. 2016. PMID: 26308771

63

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

Schlenk RF, Stegelmann F, Reiter A, Jost E, Gattermann N, Hebart H, Waller C, Hochhaus A, Platzbecker U, Schafhausen P, Blau IW, Verbeek W, Heidel FH, Werner M, Kreipe H, Teleanu V, Benner A, Döhner H, Grießhammer M, Döhner K. Schlenk RF, et al. Among authors: heidel fh. Leukemia. 2017 Apr;31(4):889-895. doi: 10.1038/leu.2016.299. Epub 2016 Oct 24. Leukemia. 2017. PMID: 27774990 Clinical Trial.

64

Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.

Palandri F, Catani L, Bonifacio M, Benevolo G, Heidel F, Palumbo GA, Crugnola M, Abruzzese E, Bartoletti D, Polverelli N, Bergamaschi M, Tiribelli M, Iurlo A, Breccia M, Cavazzini F, Tieghi A, Binotto G, Isidori A, Martino B, D'Adda M, Bosi C, Sabattini E, Vitolo U, Aversa F, Ibatici A, Lemoli RM, Sgherza N, Cuneo A, Martinelli G, Semenzato G, Cavo M, Vianelli N, Sapienza MR, Latagliata R. Palandri F, et al. Br J Haematol. 2018 Oct;183(1):35-46. doi: 10.1111/bjh.15497. Epub 2018 Jul 16. Br J Haematol. 2018. PMID: 30010187

65

Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions.

Heidel FH, Al-Ali HK, Hirt C, Kämpfe D, Jentsch-Ullrich K, Junghanss C, Nowak R, Schwarzer A, Spohn C, Vucinic V, Hochhaus A, Lange T; Working Party Myeloproliferative Neoplasms of the East German Study Group Hematology/Oncology (OSHO). Heidel FH, et al. Leukemia. 2018 Sep;32(9):2085-2087. doi: 10.1038/s41375-018-0214-x. Epub 2018 Jul 24. Leukemia. 2018. PMID: 30042412 No abstract available.

66

Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.

Palandri F, Palumbo GA, Abruzzese E, Iurlo A, Polverelli N, Elli E, Bonifacio M, Bergamaschi M, Martino B, Tiribelli M, Benevolo G, Tieghi A, Sgherza N, Isidori A, Binotto G, Crugnola M, Heidel F, Cavazzini F, Bosi C, Auteri G, Cattaneo D, Foà R, Lemoli RM, Cuneo A, Krampera M, Bartoletti D, Cavo M, Vianelli N, Breccia M, Latagliata R. Palandri F, et al. Hematol Oncol. 2019 Oct;37(4):418-423. doi: 10.1002/hon.2619. Epub 2019 Jun 7. Hematol Oncol. 2019. PMID: 30985017

67

Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety.

Schrickel L, Heidel FH, Sadjadian P, Becker T, Kolatzki V, Hochhaus A, Griesshammer M, Wille K; German Study Group MPN, GSG-MPN. Schrickel L, et al. Among authors: heidel fh. J Cancer Res Clin Oncol. 2021 May;147(5):1481-1491. doi: 10.1007/s00432-020-03430-4. Epub 2020 Nov 2. J Cancer Res Clin Oncol. 2021. PMID: 33140210

68

Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo.

Rummelt C, Gorantla SP, Meggendorfer M, Charlet A, Endres C, Döhner K, Heidel FH, Fischer T, Haferlach T, Duyster J, von Bubnoff N. Rummelt C, et al. Among authors: heidel fh. Leukemia. 2021 Jul;35(7):2017-2029. doi: 10.1038/s41375-020-01077-1. Epub 2020 Nov 4. Leukemia. 2021. PMID: 33149267

69

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.

Palandri F, Palumbo GA, Elli EM, Polverelli N, Benevolo G, Martino B, Abruzzese E, Tiribelli M, Tieghi A, Latagliata R, Cavazzini F, Bergamaschi M, Binotto G, Crugnola M, Isidori A, Caocci G, Heidel F, Pugliese N, Bosi C, Bartoletti D, Auteri G, Cattaneo D, Scaffidi L, Trawinska MM, Stella R, Ciantia F, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Iurlo A, Vianelli N, Cavo M, Breccia M, Bonifacio M. Palandri F, et al. Blood Cancer J. 2021 Jan 7;11(1):4. doi: 10.1038/s41408-020-00392-1. Blood Cancer J. 2021. PMID: 33414394 Free PMC article. No abstract available.

70

Taz protects hematopoietic stem cells from an aging-dependent decrease in PU.1 activity.

Kim KM, Mura-Meszaros A, Tollot M, Krishnan MS, Gründl M, Neubert L, Groth M, Rodriguez-Fraticelli A, Svendsen AF, Campaner S, Andreas N, Kamradt T, Hoffmann S, Camargo FD, Heidel FH, Bystrykh LV, de Haan G, von Eyss B. Kim KM, et al. Among authors: heidel fh. Nat Commun. 2022 Sep 3;13(1):5187. doi: 10.1038/s41467-022-32970-1. Nat Commun. 2022. PMID: 36057685 Free PMC article.

71

Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany.

Schmidt A, Bernhardt C, Bürkle D, Fries S, Hannig CV, Jentsch-Ullrich K, Josting A, Kreher S, Reiser M, Steinmetz HT, Tesch H, Terner S, Schulte A, Crodel CC, Palandri F, Heidel FH. Schmidt A, et al. Among authors: heidel fh. J Cancer Res Clin Oncol. 2023 Aug;149(10):7197-7206. doi: 10.1007/s00432-023-04669-3. Epub 2023 Mar 8. J Cancer Res Clin Oncol. 2023. PMID: 36884118 Free PMC article.

72

The protein deacetylase HDAC10 controls DNA replication in malignant lymphoid cells.

Mieland AO, Petrosino G, Dejung M, Chen JX, Fulzele A, Mahmoudi F, Tu JW, Mustafa AM, Zeyn Y, Hieber C, Bros M, Schnöder TM, Heidel FH, Najafi S, Oehme I, Hofmann I, Schutkowski M, Hilscher S, Kosan C, Butter F, Bhatia S, Sippl W, Krämer OH. Mieland AO, et al. Among authors: heidel fh. Leukemia. 2025 Apr 29. doi: 10.1038/s41375-025-02612-8. Online ahead of print. Leukemia. 2025. PMID: 40301616

73

LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells.

Lipka DB, Hoffmann LS, Heidel F, Markova B, Blum MC, Breitenbuecher F, Kasper S, Kindler T, Levine RL, Huber C, Fischer T. Lipka DB, et al. Mol Cancer Ther. 2008 May;7(5):1176-84. doi: 10.1158/1535-7163.MCT-07-2215. Mol Cancer Ther. 2008. PMID: 18483305

74

Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.

Markova B, Albers C, Breitenbuecher F, Melo JV, Brümmendorf TH, Heidel F, Lipka D, Duyster J, Huber C, Fischer T. Markova B, et al. Oncogene. 2010 Feb 4;29(5):739-51. doi: 10.1038/onc.2009.374. Epub 2009 Nov 2. Oncogene. 2010. PMID: 19881535

75

Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.

Uras IZ, Walter GJ, Scheicher R, Bellutti F, Prchal-Murphy M, Tigan AS, Valent P, Heidel FH, Kubicek S, Scholl C, Fröhling S, Sexl V. Uras IZ, et al. Among authors: heidel fh. Blood. 2016 Jun 9;127(23):2890-902. doi: 10.1182/blood-2015-11-683581. Epub 2016 Apr 20. Blood. 2016. PMID: 27099147 Free PMC article.

76

Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany.

Jentsch-Ullrich K, Eberhardt J, Zeremski V, Koehler M, Wolleschak D, Heidel FH. Jentsch-Ullrich K, et al. Among authors: heidel fh. J Cancer Res Clin Oncol. 2016 Sep;142(9):2041-9. doi: 10.1007/s00432-016-2209-1. Epub 2016 Jul 18. J Cancer Res Clin Oncol. 2016. PMID: 27431664

77

JAK2-V617F activates β1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1.

Gupta N, Edelmann B, Schnoeder TM, Saalfeld FC, Wolleschak D, Kliche S, Schraven B, Heidel FH, Fischer T. Gupta N, et al. Among authors: heidel fh. Leukemia. 2017 May;31(5):1223-1226. doi: 10.1038/leu.2017.26. Epub 2017 Jan 18. Leukemia. 2017. PMID: 28096537 Free PMC article. No abstract available.

78

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients.

Palandri F, Palumbo GA, Bonifacio M, Breccia M, Latagliata R, Martino B, Polverelli N, Abruzzese E, Tiribelli M, Nicolosi M, Bergamaschi M, Tieghi A, Iurlo A, Sgherza N, Cavazzini F, Isidori A, Binotto G, Ibatici A, Crugnola M, Heidel F, Bosi C, Bartoletti D, Auteri G, Catani L, Cuneo A, Aversa F, Semenzato G, Cavo M, Vianelli N, Benevolo G. Palandri F, et al. Leuk Res. 2018 Nov;74:86-88. doi: 10.1016/j.leukres.2018.10.001. Epub 2018 Oct 5. Leuk Res. 2018. PMID: 30321784 Clinical Trial. No abstract available.

79

Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.

Palandri F, Breccia M, Tiribelli M, Bonifacio M, Benevolo G, Iurlo A, Elli EM, Binotto G, Tieghi A, Polverelli N, Martino B, Abruzzese E, Bergamaschi M, Heidel FH, Cavazzini F, Crugnola M, Bosi C, Isidori A, Auteri G, Forte D, Latagliata R, Griguolo D, Cattaneo D, Trawinska M, Bartoletti D, Krampera M, Semenzato G, Lemoli RM, Cuneo A, Di Raimondo F, Vianelli N, Cavo M, Palumbo GA. Palandri F, et al. Among authors: heidel fh. Hematol Oncol. 2020 Aug;38(3):372-380. doi: 10.1002/hon.2737. Epub 2020 Apr 20. Hematol Oncol. 2020. PMID: 32271957

80

Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.

Scholl S, Fleischmann M, Schnetzke U, Heidel FH. Scholl S, et al. Among authors: heidel fh. Cells. 2020 Nov 17;9(11):2493. doi: 10.3390/cells9112493. Cells. 2020. PMID: 33212779 Free PMC article. Review.

81

Second primary malignancy in myelofibrosis patients treated with ruxolitinib.

Polverelli N, Elli EM, Abruzzese E, Palumbo GA, Benevolo G, Tiribelli M, Bonifacio M, Tieghi A, Caocci G, D'Adda M, Bergamaschi M, Binotto G, Heidel FH, Cavazzini F, Crugnola M, Pugliese N, Bosi C, Isidori A, Bartoletti D, Auteri G, Latagliata R, Gandolfi L, Martino B, Scaffidi L, Cattaneo D, D'Amore F, Trawinska MM, Stella R, Markovic U, Catani L, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Vianelli N, Breccia M, Russo D, Cavo M, Iurlo A, Palandri F. Polverelli N, et al. Among authors: heidel fh. Br J Haematol. 2021 Apr;193(2):356-368. doi: 10.1111/bjh.17192. Epub 2020 Nov 21. Br J Haematol. 2021. PMID: 33222197

82

Immunoproteasome Function in Normal and Malignant Hematopoiesis.

Tubío-Santamaría N, Ebstein F, Heidel FH, Krüger E. Tubío-Santamaría N, et al. Among authors: heidel fh. Cells. 2021 Jun 22;10(7):1577. doi: 10.3390/cells10071577. Cells. 2021. PMID: 34206607 Free PMC article. Review.

83

Oncogenic Calreticulin Induces Immune Escape by Stimulating TGFβ Expression and Regulatory T-cell Expansion in the Bone Marrow Microenvironment.

Schmidt D, Endres C, Hoefflin R, Andrieux G, Zwick M, Karantzelis N, Staehle HF, Vinnakota JM, Duquesne S, Mozaffari Jovein M, Pfeifer D, Becker H, Blazar BR, Zähringer A, Duyster J, Brummer T, Boerries M, Baumeister J, Shoumariyeh K, Li J, Green AR, Heidel FH, Tirosh I, Pahl HL, Leimkühler N, Köhler N, de Toledo MAS, Koschmieder S, Zeiser R. Schmidt D, et al. Among authors: heidel fh. Cancer Res. 2024 Sep 16;84(18):2985-3003. doi: 10.1158/0008-5472.CAN-23-3553. Cancer Res. 2024. PMID: 38885318 Free PMC article.

84

Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment - an intraindividual analysis by the German Study Group for MPN (GSG-MPN).

Manz K, Heidel FH, Koschmieder S, Schlag R, Lipke J, Stegelmann F, Griesshammer M, Klausmann M, Crodel C, Hochhaus A, Schulz H, Göthert JR, Al-Ali H, Becker H, Reiter A, Beutel G, Kricheldorf K, Brümmendorf TH, Hoffmann W, Döhner K, Isfort S; German Study Group for Myeloproliferative Neoplasms (GSG-MPN). Manz K, et al. Among authors: heidel fh. Leukemia. 2025 Apr;39(4):864-875. doi: 10.1038/s41375-025-02524-7. Epub 2025 Feb 25. Leukemia. 2025. PMID: 40000843 Free PMC article.

85

Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.

Palandri F, Tiribelli M, Benevolo G, Tieghi A, Cavazzini F, Breccia M, Bergamaschi M, Sgherza N, Polverelli N, Crugnola M, Isidori A, Binotto G, Heidel FH, Buccisano F, Martino B, Latagliata R, Spinsanti M, Kallenberg L, Palumbo GA, Abruzzese E, Scaffidi L, Cuneo A, Cavo M, Vianelli N, Bonifacio M. Palandri F, et al. Among authors: heidel fh. Hematol Oncol. 2018 Feb;36(1):285-290. doi: 10.1002/hon.2429. Epub 2017 May 17. Hematol Oncol. 2018. PMID: 28512865

86

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study^⁎.

Palandri F, Palumbo GA, Iurlo A, Polverelli N, Benevolo G, Breccia M, Abruzzese E, Tiribelli M, Bonifacio M, Tieghi A, Isidori A, Martino B, Sgherza N, D'Adda M, Bergamaschi M, Crugnola M, Cavazzini F, Bosi C, Binotto G, Auteri G, Latagliata R, Ibatici A, Scaffidi L, Penna D, Cattaneo D, Soci F, Trawinska M, Russo D, Cuneo A, Semenzato G, Di Raimondo F, Aversa F, Lemoli RM, Heidel F, Reggiani MLB, Bartoletti D, Cavo M, Catani L, Vianelli N. Palandri F, et al. Semin Hematol. 2018 Oct;55(4):248-255. doi: 10.1053/j.seminhematol.2018.05.013. Epub 2018 Jun 5. Semin Hematol. 2018. PMID: 30502854

87

Context-specific effects of NOX4 inactivation in acute myeloid leukemia (AML).

Demircan MB, Schnoeder TM, Mgbecheta PC, Schröder K, Böhmer FD, Heidel FH. Demircan MB, et al. Among authors: heidel fh. J Cancer Res Clin Oncol. 2022 Aug;148(8):1983-1990. doi: 10.1007/s00432-022-03986-3. Epub 2022 Mar 29. J Cancer Res Clin Oncol. 2022. PMID: 35348887 Free PMC article.

88

Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.

Palandri F, Bartoletti D, Iurlo A, Bonifacio M, Abruzzese E, Caocci G, Elli EM, Auteri G, Tiribelli M, Polverelli N, Miglino M, Heidel FH, Tieghi A, Benevolo G, Beggiato E, Fava C, Cavazzini F, Pugliese N, Binotto G, Bosi C, Martino B, Crugnola M, Ottaviani E, Micucci G, Trawinska MM, Cuneo A, Bocchia M, Krampera M, Pane F, Lemoli RM, Cilloni D, Vianelli N, Cavo M, Palumbo GA, Breccia M. Palandri F, et al. Among authors: heidel fh. Cancer. 2022 Jul 1;128(13):2449-2454. doi: 10.1002/cncr.34216. Epub 2022 Apr 1. Cancer. 2022. PMID: 35363892 Free PMC article.

89

Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study.

Palandri F, Rossi E, Auteri G, Breccia M, Paglia S, Benevolo G, Elli EM, Cavazzini F, Binotto G, Tieghi A, Tiribelli M, Heidel FH, Bonifacio M, Pugliese N, Caocci G, Crugnola M, Mendicino F, D'Addio A, Tomassetti S, Martino B, Polverelli N, Ceglie S, Mazzoni C, Mullai R, Ripamonti A, Garibaldi B, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Vianelli N, Palumbo GA, Andriani A, Cavo M, Latagliata R, De Stefano V. Palandri F, et al. Among authors: heidel fh. Cancers (Basel). 2023 Jul 21;15(14):3706. doi: 10.3390/cancers15143706. Cancers (Basel). 2023. PMID: 37509367 Free PMC article.

90

A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis.

Palandri F, Palumbo GA, Bonifacio M, Elli EM, Tiribelli M, Auteri G, Trawinska MM, Polverelli N, Benevolo G, Tieghi A, Cavalca F, Caocci G, Beggiato E, Binotto G, Cavazzini F, Miglino M, Bosi C, Crugnola M, Bocchia M, Martino B, Pugliese N, Venturi M, Isidori A, Cattaneo D, Krampera M, Pane F, Cilloni D, Semenzato G, Lemoli RM, Cuneo A, Abruzzese E, Branzanti F, Vianelli N, Cavo M, Heidel F, Iurlo A, Breccia M. Palandri F, et al. Cancers (Basel). 2023 Oct 17;15(20):5027. doi: 10.3390/cancers15205027. Cancers (Basel). 2023. PMID: 37894394 Free PMC article.

91

Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea.

Palandri F, Breccia M, Elli EM, Latagliata R, Benevolo G, Morsia E, Tiribelli M, Cavazzini F, D'Addio A, Tieghi A, Farina M, Cavalca F, Dedola A, Heidel FH, Palumbo GA, Rossi E, Branzanti F, De Stefano V. Palandri F, et al. Among authors: heidel fh. Leukemia. 2025 May 28. doi: 10.1038/s41375-025-02646-y. Online ahead of print. Leukemia. 2025. PMID: 40437171

92

Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature.

Wolleschak D, Schalk E, Krogel C, Schnoeder TM, Luehr H, Jentsch-Ullrich K, Fischer T, Heidel FH. Wolleschak D, et al. Among authors: heidel fh. J Hematol Oncol. 2013 Jun 11;6:39. doi: 10.1186/1756-8722-6-39. J Hematol Oncol. 2013. PMID: 23759001 Free PMC article. Review.

93

Leukemogenic potency of the novel FLT3-N676K mutant.

Huang K, Yang M, Pan Z, Heidel FH, Scherr M, Eder M, Fischer T, Büsche G, Welte K, von Neuhoff N, Ganser A, Li Z. Huang K, et al. Among authors: heidel fh. Ann Hematol. 2016 Apr;95(5):783-91. doi: 10.1007/s00277-016-2616-z. Epub 2016 Feb 19. Ann Hematol. 2016. PMID: 26891877

94

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.

Breccia M, Bartoletti D, Bonifacio M, Palumbo GA, Polverelli N, Abruzzese E, Bergamaschi M, Tieghi A, Tiribelli M, Iurlo A, Cavazzini F, Sgherza N, Binotto G, Isidori A, D'Adda M, Crugnola M, Bosi C, Heidel F, Molica M, Scaffidi L, Cattaneo D, Latagliata R, Auteri G, Lemoli RM, Fanin R, Russo D, Aversa F, Cuneo A, Semenzato G, Catani L, Cavo M, Vianelli N, Foà R, Palandri F. Breccia M, et al. Ann Hematol. 2019 Apr;98(4):889-896. doi: 10.1007/s00277-018-3569-1. Epub 2018 Dec 4. Ann Hematol. 2019. PMID: 30515542 Clinical Trial.

95

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.

Palandri F, Breccia M, Bonifacio M, Polverelli N, Elli EM, Benevolo G, Tiribelli M, Abruzzese E, Iurlo A, Heidel FH, Bergamaschi M, Tieghi A, Crugnola M, Cavazzini F, Binotto G, Isidori A, Sgherza N, Bosi C, Martino B, Latagliata R, Auteri G, Scaffidi L, Griguolo D, Trawinska M, Cattaneo D, Catani L, Krampera M, Lemoli RM, Cuneo A, Semenzato G, Foà R, Di Raimondo F, Bartoletti D, Cavo M, Palumbo GA, Vianelli N. Palandri F, et al. Among authors: heidel fh. Cancer. 2020 Mar 15;126(6):1243-1252. doi: 10.1002/cncr.32664. Epub 2019 Dec 20. Cancer. 2020. PMID: 31860137 Free article.

96

Impact of comorbidities and body mass index on the outcome of polycythemia vera patients.

Benevolo G, Elli EM, Bartoletti D, Latagliata R, Tiribelli M, Heidel FH, Cavazzini F, Bonifacio M, Crugnola M, Binotto G, D'Addio A, Tieghi A, Bergamaschi M, Caocci G, Polverelli N, Bossi E, Auteri G, Carmosino I, Catani L, Cuneo A, Krampera M, Lanza F, Lemoli RM, Vianelli N, Breccia M, Palumbo GA, Cavo M, Palandri F. Benevolo G, et al. Among authors: heidel fh. Hematol Oncol. 2021 Aug;39(3):409-418. doi: 10.1002/hon.2843. Epub 2021 Mar 8. Hematol Oncol. 2021. PMID: 33590502

97

Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.

Palandri F, Tiribelli M, Breccia M, Bartoletti D, Elli EM, Benevolo G, Martino B, Cavazzini F, Tieghi A, Iurlo A, Abruzzese E, Pugliese N, Binotto G, Caocci G, Auteri G, Cattaneo D, Trawinska MM, Stella R, Scaffidi L, Polverelli N, Micucci G, Masselli E, Crugnola M, Bosi C, Heidel FH, Latagliata R, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Cavo M, Vianelli N, Bonifacio M, Palumbo GA. Palandri F, et al. Among authors: heidel fh. Cancer. 2021 Aug 1;127(15):2657-2665. doi: 10.1002/cncr.33541. Epub 2021 Apr 1. Cancer. 2021. PMID: 33794557 Free article.

98

Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.

Marhäll A, Heidel F, Fischer T, Rönnstrand L. Marhäll A, et al. Ann Hematol. 2018 May;97(5):773-780. doi: 10.1007/s00277-018-3245-5. Epub 2018 Jan 25. Ann Hematol. 2018. PMID: 29372308 Free PMC article.

99

Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.

Polverelli N, Palumbo GA, Binotto G, Abruzzese E, Benevolo G, Bergamaschi M, Tieghi A, Bonifacio M, Breccia M, Catani L, Tiribelli M, D'Adda M, Sgherza N, Isidori A, Cavazzini F, Martino B, Latagliata R, Crugnola M, Heidel F, Bosi C, Ibatici A, Soci F, Penna D, Scaffidi L, Aversa F, Lemoli RM, Vitolo U, Cuneo A, Russo D, Cavo M, Vianelli N, Palandri F. Polverelli N, et al. Hematol Oncol. 2018 Apr 6. doi: 10.1002/hon.2509. Online ahead of print. Hematol Oncol. 2018. PMID: 29624703

100

A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents.

Shahswar R, Gabdoulline R, Krueger K, Wichmann M, Götze KS, Braitsch K, Meggendorfer M, Schmalbrock L, Bullinger L, Modemann F, Fiedler W, Krauter J, Kaun S, Rotermund S, Voß A, Behrens YL, Bergmann AK, Koller E, Beutel G, Thol F, Heidel F, Heuser M. Shahswar R, et al. Leukemia. 2025 Mar;39(3):614-622. doi: 10.1038/s41375-024-02501-6. Epub 2025 Jan 8. Leukemia. 2025. PMID: 39779979 Free PMC article.

101

Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.

Heidel F, Lipka DB, von Auer C, Huber C, Scharrer I, Hess G. Heidel F, et al. Thromb Haemost. 2007 Feb;97(2):228-33. doi: 10.1160/th06-09-0499. Thromb Haemost. 2007. PMID: 17264951

102

The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia.

Kasper S, Breitenbuecher F, Hoehn Y, Heidel F, Lipka DB, Markova B, Huber C, Kindler T, Fischer T. Kasper S, et al. Leuk Res. 2008 Nov;32(11):1698-708. doi: 10.1016/j.leukres.2008.05.003. Epub 2008 Jun 16. Leuk Res. 2008. PMID: 18556063

103

Severe paraneoplastic pemphigus in a patient with follicular lymphoma.

Krogel C, Fischer T, Heidel F. Krogel C, et al. Eur J Haematol. 2010 Apr;84(4):365. doi: 10.1111/j.1600-0609.2009.01362.x. Epub 2009 Oct 21. Eur J Haematol. 2010. PMID: 19845742 No abstract available.

104

Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression.

Arora D, Köthe S, van den Eijnden M, Hooft van Huijsduijnen R, Heidel F, Fischer T, Scholl S, Tölle B, Böhmer SA, Lennartsson J, Isken F, Müller-Tidow C, Böhmer FD. Arora D, et al. Cell Commun Signal. 2012 Jul 11;10(1):19. doi: 10.1186/1478-811X-10-19. Cell Commun Signal. 2012. PMID: 22784513 Free PMC article.

105

Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells.

Wagner MC, Dziadosz M, Melo JV, Heidel F, Fischer T, Lipka DB. Wagner MC, et al. Leukemia. 2013 Jul;27(7):1567-70. doi: 10.1038/leu.2012.364. Epub 2012 Dec 12. Leukemia. 2013. PMID: 23232286 No abstract available.

106

A rare cause of lower back pain.

Wolleschak D, Heidel FH. Wolleschak D, et al. Among authors: heidel fh. Blood. 2014 Jul 10;124(2):165. doi: 10.1182/blood-2014-03-565713. Blood. 2014. PMID: 25136733 Free article. No abstract available.

107

Evolutionarily conserved signaling pathways: acting in the shadows of acute myelogenous leukemia's genetic diversity.

Heidel FH, Arreba-Tutusaus P, Armstrong SA, Fischer T. Heidel FH, et al. Clin Cancer Res. 2015 Jan 15;21(2):240-8. doi: 10.1158/1078-0432.CCR-14-1436. Clin Cancer Res. 2015. PMID: 25593343 Review.

108

Prediction of central venous catheter-related bloodstream infections (CRBSIs) in patients with haematologic malignancies using a modified Infection Probability Score (mIPS).

Schalk E, Hanus L, Färber J, Fischer T, Heidel FH. Schalk E, et al. Among authors: heidel fh. Ann Hematol. 2015 Sep;94(9):1451-6. doi: 10.1007/s00277-015-2387-y. Epub 2015 May 3. Ann Hematol. 2015. PMID: 25933677 Clinical Trial.

109

Central Venous Catheter-Related Bloodstream Infections in Obese Hematologic Patients.

Schalk E, Färber J, Fischer T, Heidel FH. Schalk E, et al. Among authors: heidel fh. Infect Control Hosp Epidemiol. 2015 Aug;36(8):995-6. doi: 10.1017/ice.2015.107. Epub 2015 May 20. Infect Control Hosp Epidemiol. 2015. PMID: 25990462 Clinical Trial. No abstract available.

110

Chronic myelogenous leukemia evolving after treatment of multiple myeloma.

Wolleschak D, Heidel FH. Wolleschak D, et al. Among authors: heidel fh. Blood. 2016 Jul 7;128(1):146. doi: 10.1182/blood-2016-03-706945. Blood. 2016. PMID: 28092869 Free article. No abstract available.

111

Influence of Scribble polarity complex on hematopoiesis and leukemia - a matter of where, when and how.

Heidel FH, Ellis S. Heidel FH, et al. Oncotarget. 2018 Oct 5;9(78):34642-34643. doi: 10.18632/oncotarget.26132. eCollection 2018 Oct 5. Oncotarget. 2018. PMID: 30410664 Free PMC article. No abstract available.

112

Epigenetic Erosion in Adult Stem Cells: Drivers and Passengers of Aging.

Kosan C, Heidel FH, Godmann M, Bierhoff H. Kosan C, et al. Among authors: heidel fh. Cells. 2018 Nov 29;7(12):237. doi: 10.3390/cells7120237. Cells. 2018. PMID: 30501028 Free PMC article. Review.

113

Molecular Mechanisms of Senescence and Implications for the Treatment of Myeloid Malignancies.

Ernst P, Heidel FH. Ernst P, et al. Among authors: heidel fh. Cancers (Basel). 2021 Feb 4;13(4):612. doi: 10.3390/cancers13040612. Cancers (Basel). 2021. PMID: 33557090 Free PMC article. Review.

114

The Role of MacroH2A Histone Variants in Cancer.

Hsu CJ, Meers O, Buschbeck M, Heidel FH. Hsu CJ, et al. Among authors: heidel fh. Cancers (Basel). 2021 Jun 15;13(12):3003. doi: 10.3390/cancers13123003. Cancers (Basel). 2021. PMID: 34203934 Free PMC article. Review.

115

Recurrent Upper Gastrointestinal Bleeding from Isolated Gastric Varices as Primary Symptom of Myelofibrosis: A Case Report on Combining Interventional and Pharmacologic Treatment Options.

Giszas B, Weber M, Heidel FH, Reuken PA. Giszas B, et al. Among authors: heidel fh. Dig Dis. 2022;40(4):530-534. doi: 10.1159/000518766. Epub 2021 Aug 2. Dig Dis. 2022. PMID: 34348280

116

Combined Activity of the Redox-Modulating Compound Setanaxib (GKT137831) with Cytotoxic Agents in the Killing of Acute Myeloid Leukemia Cells.

Demircan MB, Mgbecheta PC, Kresinsky A, Schnoeder TM, Schröder K, Heidel FH, Böhmer FD. Demircan MB, et al. Among authors: heidel fh. Antioxidants (Basel). 2022 Mar 8;11(3):513. doi: 10.3390/antiox11030513. Antioxidants (Basel). 2022. PMID: 35326163 Free PMC article.

117

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.

Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH, Brandts C, Serve H, Roesel J, Giles F, Feldman E, Ehninger G, Schiller GJ, Nimer S, Stone RM, Wang Y, Kindler T, Cohen PS, Huber C, Fischer T. Heidel F, et al. Blood. 2006 Jan 1;107(1):293-300. doi: 10.1182/blood-2005-06-2469. Epub 2005 Sep 8. Blood. 2006. PMID: 16150941 Free article.

118

Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.

Heidel F, Cortes J, Rücker FG, Aulitzky W, Letvak L, Kindler T, Huber C, Döhner H, Kantarjian H, Fischer T. Heidel F, et al. Cancer. 2007 Mar 1;109(5):907-14. doi: 10.1002/cncr.22471. Cancer. 2007. PMID: 17285599 Free article. Clinical Trial.

119

Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies.

Kasper S, Breitenbuecher F, Heidel F, Hoffarth S, Markova B, Schuler M, Fischer T. Kasper S, et al. Blood Cancer J. 2012 Mar;2(3):e60. doi: 10.1038/bcj.2012.5. Epub 2012 Mar 9. Blood Cancer J. 2012. PMID: 22829255 Free PMC article.

120

Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.

Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Krämer A, Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, Scholl C, Fröhling S. Placke T, et al. Among authors: heidel fh. Blood. 2014 Jul 3;124(1):13-23. doi: 10.1182/blood-2014-02-558114. Epub 2014 Apr 24. Blood. 2014. PMID: 24764564 Free PMC article.

121

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.

Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S; COMFORT Investigators. Vannucchi AM, et al. Haematologica. 2015 Sep;100(9):1139-45. doi: 10.3324/haematol.2014.119545. Epub 2015 Jun 11. Haematologica. 2015. PMID: 26069290 Free PMC article. Clinical Trial.

122

Leukemic mastopathy.

Schalk E, Heidel FH. Schalk E, et al. Among authors: heidel fh. Int J Hematol. 2016 Apr;103(4):357-8. doi: 10.1007/s12185-016-1948-8. Epub 2016 Feb 8. Int J Hematol. 2016. PMID: 26857154 No abstract available.

123

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.

Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, Montesinos P, Pollyea DA, DesJardins P, Ottmann O, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Heuser M. Cortes JE, et al. Among authors: heidel fh. Leukemia. 2019 Feb;33(2):379-389. doi: 10.1038/s41375-018-0312-9. Epub 2018 Dec 16. Leukemia. 2019. PMID: 30555165 Free PMC article. Clinical Trial.

124

The Genomic Landscape of Myeloid Malignancies: Options for Pan-myeloid Therapies?

Heidel FH, Platzbecker U. Heidel FH, et al. Hemasphere. 2021 Feb 10;5(3):e537. doi: 10.1097/HS9.0000000000000537. eCollection 2021 Mar. Hemasphere. 2021. PMID: 33604515 Free PMC article. No abstract available.

125

Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry.

Gecht J, Tsoukakis I, Kricheldorf K, Stegelmann F, Klausmann M, Griesshammer M, Schulz H, Hollburg W, Göthert JR, Sockel K, Heidel FH, Gattermann N, Maintz C, Al-Ali HK, Platzbecker U, Hansen R, Hänel M, Parmentier S, Bommer M, Pahl HL, Lang F, Kirschner M, Isfort S, Brümmendorf TH, Döhner K, Koschmieder S. Gecht J, et al. Among authors: heidel fh. Cancers (Basel). 2021 Aug 13;13(16):4086. doi: 10.3390/cancers13164086. Cancers (Basel). 2021. PMID: 34439237 Free PMC article.

126

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis.

Harrison C, Heidel FH, Vannucchi AM, Kiladjian JJ, Hayat A, Passamonti F, Conneally E, Kindler T, Martino B, Lipka DB, Stefanelli T, Roussou P, Germano D, Ewan J, Ribrag V. Harrison C, et al. Among authors: heidel fh. Hemasphere. 2022 Aug 2;6(8):e757. doi: 10.1097/HS9.0000000000000757. eCollection 2022 Aug. Hemasphere. 2022. PMID: 35935608 Free PMC article. No abstract available.

127

Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.

Mahboobi S, Uecker A, Sellmer A, Cénac C, Höcher H, Pongratz H, Eichhorn E, Hufsky H, Trümpler A, Sicker M, Heidel F, Fischer T, Stocking C, Elz S, Böhmer FD, Dove S. Mahboobi S, et al. J Med Chem. 2006 Jun 1;49(11):3101-15. doi: 10.1021/jm058033i. J Med Chem. 2006. PMID: 16722630

128

A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells.

Graf C, Heidel F, Tenzer S, Radsak MP, Solem FK, Britten CM, Huber C, Fischer T, Wölfel T. Graf C, et al. Blood. 2007 Apr 1;109(7):2985-8. doi: 10.1182/blood-2006-07-032839. Blood. 2007. PMID: 17119119 Free article.

129

Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients.

Al-Batran SE, Hartmann JT, Heidel F, Stoehlmacher J, Wardelmann E, Dechow C, Düx M, Izbicki JR, Kraus T, Fischer T, Jäger E. Al-Batran SE, et al. Gastric Cancer. 2007;10(3):145-52. doi: 10.1007/s10120-007-0425-8. Epub 2007 Sep 26. Gastric Cancer. 2007. PMID: 17922091

130

Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.

Lyros O, Mueller A, Heidel F, Schimanski CC, Gockel I, Galle PR, Lang H, Moehler M. Lyros O, et al. Int J Cancer. 2010 Sep 1;127(5):1197-208. doi: 10.1002/ijc.25137. Int J Cancer. 2010. PMID: 20039326

131

Self-renewal related signaling in myeloid leukemia stem cells.

Heidel FH, Mar BG, Armstrong SA. Heidel FH, et al. Int J Hematol. 2011 Aug;94(2):109-117. doi: 10.1007/s12185-011-0901-0. Epub 2011 Jul 29. Int J Hematol. 2011. PMID: 21800073 Free PMC article. Review.

132

Germ and hematology: underlying disease influences diversity of germ spectra and antibiotic therapy.

Schalk E, Tammer I, Heidel FH. Schalk E, et al. Among authors: heidel fh. Infect Control Hosp Epidemiol. 2014 Feb;35(2):208-10. doi: 10.1086/674864. Infect Control Hosp Epidemiol. 2014. PMID: 24442091 No abstract available.

133

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy.

Cortes JE, Heidel FH, Fiedler W, Smith BD, Robak T, Montesinos P, Candoni A, Leber B, Sekeres MA, Pollyea DA, Ferdinand R, Ma WW, O'Brien T, O'Connell A, Chan G, Heuser M. Cortes JE, et al. Among authors: heidel fh. J Hematol Oncol. 2020 Jul 14;13(1):92. doi: 10.1186/s13045-020-00929-8. J Hematol Oncol. 2020. PMID: 32664995 Free PMC article.

134

Rhabdomyolysis induced by nelarabine.

Späth C, Schönau M, Gaubert S, Neumann T, Schmidt CA, Heidel FH, Krüger WH. Späth C, et al. Among authors: heidel fh. Ann Hematol. 2022 Sep;101(9):2111-2112. doi: 10.1007/s00277-022-04879-8. Epub 2022 Jun 17. Ann Hematol. 2022. PMID: 35715705 Free PMC article. No abstract available.

135

The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms.

Kühn MWM, Pemmaraju N, Heidel FH. Kühn MWM, et al. Among authors: heidel fh. Leukemia. 2025 May 15. doi: 10.1038/s41375-025-02639-x. Online ahead of print. Leukemia. 2025. PMID: 40374809 Review.

136

Biased distribution of chromosomal breakpoints involving the MLL gene in infants versus children and adults with t(4;11) ALL.

Reichel M, Gillert E, Angermüller S, Hensel JP, Heidel F, Lode M, Leis T, Biondi A, Haas OA, Strehl S, Panzer-Grümayer ER, Griesinger F, Beck JD, Greil J, Fey GH, Uckun FM, Marschalek R. Reichel M, et al. Oncogene. 2001 May 24;20(23):2900-7. doi: 10.1038/sj.onc.1204401. Oncogene. 2001. PMID: 11420702

137

Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review.

Passamonti F, Heidel FH, Parikh RC, Ajmera M, Tang D, Nadal JA, Davis KL, Abraham P. Passamonti F, et al. Among authors: heidel fh. Future Oncol. 2022 Jun;18(18):2217-2231. doi: 10.2217/fon-2021-1358. Epub 2022 Apr 7. Future Oncol. 2022. PMID: 35388710 Free article.

138

Significance of men's health in long-term survivors of allogeneic stem cell transplantation.

Schneidewind L, Neumann T, Peters N, Kranz J, Probst KA, Heidel FH, Hakenberg OW, Krüger W. Schneidewind L, et al. Among authors: heidel fh. Bone Marrow Transplant. 2022 Jun;57(6):998-1000. doi: 10.1038/s41409-022-01638-1. Epub 2022 Mar 25. Bone Marrow Transplant. 2022. PMID: 35338338 Free PMC article. No abstract available.

139

Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: analysis on 6849 participants of the SHIP-study.

Manz K, Bahr J, Ittermann T, Döhner K, Koschmieder S, Brümmendorf TH, Griesshammer M, Nauck M, Völzke H, Heidel FH. Manz K, et al. Among authors: heidel fh. Leukemia. 2023 Aug;37(8):1745-1749. doi: 10.1038/s41375-023-01943-8. Epub 2023 Jun 23. Leukemia. 2023. PMID: 37353711 Free PMC article. No abstract available.

140

ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis.

Ross DM, Heidel FH, Perkins AC, Reiter A, Crodel CC, Riley CH, Gómez Casares MT, Takacs I, Becker H, Lehmann T, Vinogradova OY, Burbury K, Vannucchi AM, Gupta V, Wondergem MJ, Kiladjian JJ, Cleary G, Zhang A, Kota J, Prahallad AC, Wroclawska M, Lu M, Harrison CN. Ross DM, et al. Among authors: heidel fh. Blood Adv. 2025 May 7:bloodadvances.2025015860. doi: 10.1182/bloodadvances.2025015860. Online ahead of print. Blood Adv. 2025. PMID: 40334082

141

Significance of BK Polyomavirus in Long-Term Survivors after Adult Allogeneic Stem Cell Transplantation.

Neumann T, Peters N, Kranz J, Dräger DL, Heidel FH, Krüger W, Schneidewind L. Neumann T, et al. Among authors: heidel fh. Biology (Basel). 2021 Jun 19;10(6):553. doi: 10.3390/biology10060553. Biology (Basel). 2021. PMID: 34205390 Free PMC article.

142

Enhancer hijacking discovery in acute myeloid leukemia by pyjacker identifies MNX1 activation via deletion 7q.

Sollier E, Riedel A, Toprak UH, Wierzbinska JA, Weichenhan D, Schmid JP, Hakobyan M, Touzart A, Jahn E, Vick B, Brown-Burke F, Kelly K, Kelekci S, Pejkovska A, Goyal A, Bähr M, Breuer K, Chen MM, Llamazares-Prada M, Hartmann M, Schönung M, Correia N, Trumpp A, Abdullah Y, Klingmüller U, Mughal SS, Brors B, Westermann F, Ulrich E, Autry RJ, Schlesner M, Vosberg S, Herold T, Greif PA, Pfeifer D, Lübbert M, Fischer T, Heidel FH, Gebhard C, Walter W, Haferlach T, Eisfeld AK, Mrózek K, Nicolet D, Bullinger L, Smeenk L, Erpelinck-Verschueren C, Mulet-Lazaro R, Delwel R, Ernst A, Scherer M, Lutsik P, Jeremias I, Döhner K, Döhner H, Lipka DB, Plass C. Sollier E, et al. Among authors: heidel fh. Blood Cancer Discov. 2025 Mar 31. doi: 10.1158/2643-3230.BCD-24-0278. Online ahead of print. Blood Cancer Discov. 2025. PMID: 40162972

143

How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024.

Griesshammer M, Al-Ali HK, Eckardt JN, Fiegl M, Göthert J, Jentsch-Ullrich K, Koschmieder S, Kvasnicka HM, Reiter A, Schmidt B, Heidel FH. Griesshammer M, et al. Among authors: heidel fh. Ann Hematol. 2025 Jan;104(1):295-306. doi: 10.1007/s00277-025-06191-7. Epub 2025 Jan 31. Ann Hematol. 2025. PMID: 39888352 Free PMC article.

144

Anti-CD19 CAR-T cell therapy for acquired hemophilia A.

Schultze-Florey CR, Thol FR, Aleksandrova K, Stoyanov K, Gutierrez Jauregui R, Arseniev L, Leise J, Klöß S, Heidel FH, Tiede A. Schultze-Florey CR, et al. Among authors: heidel fh. Leukemia. 2025 Apr;39(4):980-982. doi: 10.1038/s41375-025-02554-1. Epub 2025 Mar 8. Leukemia. 2025. PMID: 40057635 Free PMC article. No abstract available.

145

Prediction of resistance to hydroxyurea therapy in patients with polycythemia vera: a machine learning study (PV-AIM) validated in a prospective interventional phase IV trial (HU-F-AIM).

Heidel FH, De Stefano V, Zaiss M, Kisro J, Gückel E, Großer S, Zuurman MW, Manz K, Bryan K, Afsharinejad A, Griesshammer M, Kiladjian JJ. Heidel FH, et al. Leukemia. 2025 Apr 25. doi: 10.1038/s41375-025-02623-5. Online ahead of print. Leukemia. 2025. PMID: 40281326

146

Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemia.

Mecklenbrauck R, Borchert N, Gabdoulline R, Poll P, Funke C, Brandes M, Dallmann LK, Fiedler W, Krauter J, Trummer A, Hertenstein B, Müller M, Lübbert M, Schwalenberg M, Voss A, Di Donato N, Bergmann A, Gaidzik V, Döhner K, Döhner H, Ganser A, Heidel FH, Thol FR, Heuser M. Mecklenbrauck R, et al. Among authors: heidel fh. Leukemia. 2025 Apr 28. doi: 10.1038/s41375-025-02622-6. Online ahead of print. Leukemia. 2025. PMID: 40295828 No abstract available.

147

Impact of adding carboplatin to docetaxel chemotherapy on testosterone levels and treatment outcomes in metastatic docetaxel-resistant prostate cancer.

Atalan H, Morgan MA, Ivanyi P, Kappler P, Heidel FH, Reuter CWM. Atalan H, et al. Among authors: heidel fh. Sci Rep. 2025 Jun 20;15(1):20130. doi: 10.1038/s41598-025-04667-0. Sci Rep. 2025. PMID: 40542015 Free PMC article.

148

Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study.

Palandri F, Breccia M, Morsia E, Elli EM, Benevolo G, Tiribelli M, Beggiato E, Farina M, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Isidori A, Dedola A, Scalzulli E, Moioli A, Cavalca F, Caserta S, Duminuco A, Martino B, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Bonifacio M, Palumbo GA, Branzanti F, Iurlo A, Abruzzese E. Palandri F, et al. Among authors: heidel fh. Leuk Res. 2025 Jul;154:107719. doi: 10.1016/j.leukres.2025.107719. Epub 2025 May 27. Leuk Res. 2025. PMID: 40460507 No abstract available.

149

Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma.

Shumilov E, Scholz JK, Seib M, Mazzeo P, Wurm-Kuczera R, Vucinic V, Holtick U, Boyadzhiev H, Melchardt T, Hölscher AS, Schultze-Florey CR, Abdelhafez A, Velazquez GF, Ossami Saidy A, Lesan V, Schnetzke U, Kerkhoff A, Bacher U, Ghandili S, Aydilek E, Gebauer N, Weber T, Wulf GG, Glass B, Thurner L, Heidel FH, Schmid C, Viardot A, Hänel M, Dietrich S, Pabst T, Ayuk FA, von Tresckow B, Chapuy B, Pott C, Müller F, Lenz G. Shumilov E, et al. Among authors: heidel fh. Blood Adv. 2025 Apr 16:bloodadvances.2024015719. doi: 10.1182/bloodadvances.2024015719. Online ahead of print. Blood Adv. 2025. PMID: 40238938

150

Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis.

Palandri F, Breccia M, Morsia E, Elli EM, Benevolo G, Tiribelli M, Beggiato E, Farina M, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Isidori A, Dedola A, Iurlo A, Lemoli RM, Cilloni D, Bocchia M, Heidel FH, Bonifacio M, Palumbo GA, Branzanti F. Palandri F, et al. Among authors: heidel fh. Clin Lymphoma Myeloma Leuk. 2025 Jul;25(7):e524-e532.e3. doi: 10.1016/j.clml.2025.02.015. Epub 2025 Mar 4. Clin Lymphoma Myeloma Leuk. 2025. PMID: 40133140

151

Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: Insights from the Landmark 2.0 global health survey.

Harrison CN, Ross DM, Fogliatto LM, Foltz L, Busque L, Xiao Z, Heidel FH, Koehler M, Palumbo GA, Breccia M, Komatsu N, Kirito K, Xicoy Cirici B, Martinez-Lopez J, Rovo A, Petruk C, Bobirca C, Mirams L, McMillan A, Harper G, Kiladjian JJ. Harrison CN, et al. Among authors: heidel fh. Hemasphere. 2025 Mar 24;9(3):e70106. doi: 10.1002/hem3.70106. eCollection 2025 Mar. Hemasphere. 2025. PMID: 40130070 Free PMC article.

152

Mitigation of atrial fibrillation-related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG-MPN bioregistry.

Cho HR, Isfort S, Kricheldorf K, Stegelmann F, Klausmann M, Heidel FH, Griesshammer M, Schulz H, Hochhaus A, Göthert J, Schlag R, Hollburg W, Teichmann L, Sockel K, Wilop S, Gezer D, Kirschner M, Döhner K, Brümmendorf TH, Koschmieder S; German Study Group for Myeloproliferative Neoplasms (GSG‐MPN). Cho HR, et al. Among authors: heidel fh. Hemasphere. 2025 Mar 17;9(3):e70090. doi: 10.1002/hem3.70090. eCollection 2025 Mar. Hemasphere. 2025. PMID: 40098896 Free PMC article. No abstract available.

153

Cell-free DNA for detection and monitoring of extramedullary AML relapse.

Hupe HC, Wienecke CP, Bartels S, Schipper E, Leßmann J, Lasch A, Bader M, Gabdoulline R, Neugebohren M, Dammann E, Kreipe HH, Lehmann U, Bergmann AK, Di Donato N, Stadler M, Eder M, Ganser A, Heidel FH, Thol F, Heuser M. Hupe HC, et al. Among authors: heidel fh. Hemasphere. 2025 Mar 10;9(3):e70097. doi: 10.1002/hem3.70097. eCollection 2025 Mar. Hemasphere. 2025. PMID: 40066001 Free PMC article.

154

Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the ICOG Study.

Wiegmann JP, Fröhlich T, Möhn N, Duzzi L, Narten E, Aurich J, Thomas J, Grote-Levi L, Mahjoub S, Berliner D, Wirth T, Golpon H, Bollmann BA, Von Wasilewski I, Gutzmer R, Heidel FH, Skripuletz T, Beutel G, Ivanyi P; ICOG‐CCCH (Immune Cooperative Oncology Group, Comprehensive Cancer Center Hannover). Wiegmann JP, et al. Among authors: heidel fh. Cancer Med. 2025 Feb;14(3):e70582. doi: 10.1002/cam4.70582. Cancer Med. 2025. PMID: 39865401 Free PMC article.

155

Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy.

Palandri F, Branzanti F, Morsia E, Dedola A, Benevolo G, Tiribelli M, Beggiato E, Farina M, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Isidori A, Scalzulli E, D'Agostino D, Caserta S, Nardo A, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Palumbo GA, Breccia M, Elli EM, Bonifacio M. Palandri F, et al. Among authors: heidel fh. Ann Hematol. 2025 Jan;104(1):241-251. doi: 10.1007/s00277-025-06204-5. Epub 2025 Jan 20. Ann Hematol. 2025. PMID: 39831987 Free PMC article.

156

Pathogenesis and management of high molecular risk myeloproliferative neoplasms.

Ling VY, Heidel FH, Bywater MJ. Ling VY, et al. Among authors: heidel fh. Haematologica. 2025 Apr 1;110(4):863-876. doi: 10.3324/haematol.2023.283987. Epub 2024 Dec 5. Haematologica. 2025. PMID: 39633552 Free PMC article. Review.

157

Correction: Significance of men's health in long-term survivors of allogeneic stem cell transplantation.

Schneidewind L, Neumann T, Peters N, Kranz J, Probst KA, Heidel FH, Hakenberg OW, Krüger W. Schneidewind L, et al. Among authors: heidel fh. Bone Marrow Transplant. 2024 Dec;59(12):1789. doi: 10.1038/s41409-024-02415-y. Bone Marrow Transplant. 2024. PMID: 39367229 Free PMC article. No abstract available.

158

Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.

Palandri F, Elli EM, Morsia E, Benevolo G, Tiribelli M, Beggiato E, Bonifacio M, Farina M, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Iurlo A, Isidori A, Bosi C, Guglielmana V, Venturi M, Dedola A, Loffredo M, Fontana G, Duminuco A, Moioli A, Tosoni L, Scalzulli E, Cattaneo D, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Vianelli N, Cavo M, Palumbo GA, Branzanti F, Breccia M. Palandri F, et al. Among authors: heidel fh. Cancer. 2024 Dec 15;130(24):4257-4266. doi: 10.1002/cncr.35489. Epub 2024 Jul 30. Cancer. 2024. PMID: 39078647 Free PMC article.

159

ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.

Kiladjian JJ, Marin FF, Al-Ali HK, Alvarez-Larrán A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan AM, Danaila CD, De Stefano V, Döhner K, Empson V, Gora-Tybor J, Griesshammer M, Grosicki S, Guglielmelli P, García-Gutierrez V, Heidel FH, Illés A, Tomuleasa C, James C, Koschmieder S, Krauth MT, Krejcy K, Lazaroiu MC, Mayer J, Nagy ZG, Nicolini FE, Palandri F, Pappa V, Reiter AJ, Sacha T, Schlager S, Schmidt S, Terpos E, Unger M, Wölfler A, Cirici BX, Klade C. Kiladjian JJ, et al. Among authors: heidel fh. Ann Hematol. 2024 Jul;103(7):2299-2310. doi: 10.1007/s00277-024-05665-4. Epub 2024 Mar 4. Ann Hematol. 2024. PMID: 38438627 Free PMC article.

160

Aggregates of nonmuscular myosin IIA in erythrocytes associate with GATA1- and GFI1B-related thrombocytopenia.

Zaninetti C, Rivera J, Vater L, Ohlenforst S, Leinøe E, Böckelmann D, Freson K, Thiele T, Makhloufi H, Rath M, Eberl W, Wolff M, Freyer C, Wesche J, Zieger B, Felbor U, Heidel FH, Greinacher A. Zaninetti C, et al. Among authors: heidel fh. J Thromb Haemost. 2024 Apr;22(4):1179-1186. doi: 10.1016/j.jtha.2023.12.007. Epub 2023 Dec 15. J Thromb Haemost. 2024. PMID: 38103735 Free article.

161

Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia.

Bruedigam C, Porter AH, Song A, Vroeg In de Wei G, Stoll T, Straube J, Cooper L, Cheng G, Kahl VFS, Sobinoff AP, Ling VY, Jebaraj BMC, Janardhanan Y, Haldar R, Bray LJ, Bullinger L, Heidel FH, Kennedy GA, Hill MM, Pickett HA, Abdel-Wahab O, Hartel G, Lane SW. Bruedigam C, et al. Among authors: heidel fh. Nat Cancer. 2024 Jan;5(1):47-65. doi: 10.1038/s43018-023-00653-5. Epub 2023 Oct 30. Nat Cancer. 2024. PMID: 37904045 Free PMC article. Clinical Trial.

162

Associations of spleen volume with markers of blood count and lipid profile in a large population-based study.

Naeem M, Ittermann T, Markus MRP, Mousa MFM, von Heder L, Bülow R, Dörr M, Nauck M, Agdassi A, Heidel FH, Völzke H. Naeem M, et al. Among authors: heidel fh. Ups J Med Sci. 2023 Sep 15;128. doi: 10.48101/ujms.v128.9785. eCollection 2023. Ups J Med Sci. 2023. PMID: 37807997 Free PMC article.

163

Patients receiving allogeneic haematopoietic stem-cell transplantation and clinical outcomes after early access to palliative care.

Späth C, Neumann T, Schmidt CA, Heidel FH, Krüger WH. Späth C, et al. Among authors: heidel fh. Lancet Haematol. 2023 Sep;10(9):e777-e784. doi: 10.1016/S2352-3026(23)00114-X. Epub 2023 Jul 25. Lancet Haematol. 2023. PMID: 37506724 Review.

164

Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms.

Hinze A, Rinke J, Crodel CC, Möbius S, Schäfer V, Heidel FH, Hochhaus A, Ernst T. Hinze A, et al. Among authors: heidel fh. Br J Haematol. 2023 Jul;202(2):308-317. doi: 10.1111/bjh.18834. Epub 2023 May 4. Br J Haematol. 2023. PMID: 37139709

165

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.

Palandri F, Elli EM, Auteri G, Bonifacio M, Benevolo G, Heidel FH, Paglia S, Trawinska MM, Bosi C, Rossi E, Tiribelli M, Tieghi A, Iurlo A, Polverelli N, Caocci G, Binotto G, Cavazzini F, Beggiato E, Cilloni D, Tatarelli C, Mendicino F, Miglino M, Bocchia M, Crugnola M, Mazzoni C, Romagnoli AD, Rindone G, Ceglie S, D'Addio A, Santoni E, Cattaneo D, Bartoletti D, Lemoli RM, Krampera M, Cuneo A, Semenzato GC, Latagliata R, Abruzzese E, Vianelli N, Cavo M, Andriani A, De Stefano V, Palumbo GA, Breccia M. Palandri F, et al. Among authors: heidel fh. Blood Cancer J. 2023 May 3;13(1):65. doi: 10.1038/s41408-023-00834-6. Blood Cancer J. 2023. PMID: 37137878 Free PMC article. No abstract available.

166

Antiseptic efficacy of two mouth rinses in the oral cavity to identify a suitable rinsing solution in radiation- or chemotherapy induced mucositis.

Zwicker P, Freitag M, Heidel FH, Kocher T, Kramer A. Zwicker P, et al. Among authors: heidel fh. BMC Oral Health. 2023 Mar 26;23(1):176. doi: 10.1186/s12903-023-02884-5. BMC Oral Health. 2023. PMID: 36966298 Free PMC article. Clinical Trial.

167

Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.

Palandri F, Breccia M, Mazzoni C, Auteri G, Elli EM, Trawinska MM, Polverelli N, Tiribelli M, Benevolo G, Iurlo A, Tieghi A, Heidel FH, Caocci G, Beggiato E, Binotto G, Cavazzini F, Miglino M, Bosi C, Crugnola M, Bocchia M, Martino B, Pugliese N, Biondo M, Venturi M, Scaffidi L, Isidori A, Cattaneo D, Krampera M, Pane F, Cilloni D, Semenzato G, Lemoli RM, Cuneo A, Abruzzese E, Bartoletti D, Paglia S, Vianelli N, Cavo M, Bonifacio M, Palumbo GA. Palandri F, et al. Among authors: heidel fh. Cancer. 2023 Jun 1;129(11):1704-1713. doi: 10.1002/cncr.34722. Epub 2023 Mar 18. Cancer. 2023. PMID: 36932983 Free article.

168

Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN).

Stegelmann F, Teichmann LL, Heidel FH, Crodel CC, Ernst T, Kreil S, Reiter A, Otten S, Schauer S, Körber RM, Kricheldorf K, Isfort S, Döhner H, Brümmendorf TH, Griesshammer M, Döhner K, Koschmieder S. Stegelmann F, et al. Among authors: heidel fh. Leukemia. 2023 Apr;37(4):924-928. doi: 10.1038/s41375-023-01837-9. Epub 2023 Feb 24. Leukemia. 2023. PMID: 36828867 Free PMC article. No abstract available.

169

Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia.

Straube J, Eifert T, Vu T, Janardhanan Y, Haldar R, von Eyss B, Cooper L, Bruedigam C, Ling VY, Cooper E, Patch AM, Bullinger L, Schnoeder TM, Bywater M, Heidel FH, Lane SW. Straube J, et al. Among authors: heidel fh. Leukemia. 2023 Apr;37(4):741-750. doi: 10.1038/s41375-023-01832-0. Epub 2023 Feb 4. Leukemia. 2023. PMID: 36739348 Free PMC article.

170

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.

Koschmieder S, Isfort S, Wolf D, Heidel FH, Hochhaus A, Schafhausen P, Griesshammer M, Wolleschak D, Platzbecker U, Döhner K, Jost PJ, Parmentier S, Schaich M, von Bubnoff N, Stegelmann F, Maurer A, Crysandt M, Gezer D, Kortmann M, Franklin J, Frank J, Hellmich M, Brümmendorf TH; German Study Group for Myeloproliferative Neoplasms (GSG-MPN). Koschmieder S, et al. Among authors: heidel fh. Ann Hematol. 2023 Feb;102(2):349-358. doi: 10.1007/s00277-022-05080-7. Epub 2022 Dec 23. Ann Hematol. 2023. PMID: 36564535 Free PMC article. Clinical Trial.

171

Comparison of inpatient and outpatient palliative sedation practice - A prospective observational study.

Buchhold B, Jülich A, Glöckner F, Neumann T, Schneidewind L, Schmidt CA, Heidel FH, Krüger WH. Buchhold B, et al. Among authors: heidel fh. Palliat Support Care. 2024 Aug;22(4):637-643. doi: 10.1017/S1478951522001523. Palliat Support Care. 2024. PMID: 36397281

172

Breakthrough infections in MPN-COVID vaccinated patients.

Barbui T, Carobbio A, Ghirardi A, Iurlo A, De Stefano V, Sobas MA, Rumi E, Elli EM, Lunghi F, Gasior Kabat M, Cuevas B, Guglielmelli P, Bonifacio M, Marchetti M, Alvarez-Larran A, Fox L, Bellini M, Daffini R, Benevolo G, Carreno-Tarragona G, Patriarca A, Al-Ali HK, Andrade-Campos MMM, Palandri F, Harrison C, Foncillas MA, Osorio S, Koschmieder S, Magro Mazo E, Kiladjian JJ, Bolaños Calderón E, Heidel FH, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Sanchez AM, Hernandez-Boluda JC, Lopez Abadia E, Carli G, Sagues Serrano M, Kusec R, Xicoy Cirici B, Guenova M, Navas Elorza B, Angona A, Cichocka E, Kulikowska de Nałęcz A, Cattaneo D, Bucelli C, Betti S, Borsani O, Cavalca F, Carbonell S, Curto-Garcia N, Benajiba L, Rambaldi A, Vannucchi AM. Barbui T, et al. Among authors: heidel fh. Blood Cancer J. 2022 Nov 15;12(11):154. doi: 10.1038/s41408-022-00749-8. Blood Cancer J. 2022. PMID: 36379921 Free PMC article. No abstract available.

173

Dynamic DNA methylation reveals novel cis-regulatory elements in mouse hematopoiesis.

Schönung M, Hartmann M, Krämer S, Stäble S, Hakobyan M, Kleinert E, Aurich T, Cobanoglu D, Heidel FH, Fröhling S, Milsom MD, Schlesner M, Lutsik P, Lipka DB. Schönung M, et al. Among authors: heidel fh. Exp Hematol. 2023 Jan;117:24-42.e7. doi: 10.1016/j.exphem.2022.11.001. Epub 2022 Nov 8. Exp Hematol. 2023. PMID: 36368558 Free article.

174

Oncogenic JAK2^V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.

Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M, Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel FH, Kröger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R. Prestipino A, et al. Among authors: heidel fh. Sci Transl Med. 2018 Feb 21;10(429):eaam7729. doi: 10.1126/scitranslmed.aam7729. Sci Transl Med. 2018. PMID: 29467301 Free PMC article.

175

Macrophage's little helper: vitamin A directs alternatively activated monocyte-derived macrophages to tissue-resident macrophages.

Schlüter D, Heidel FH. Schlüter D, et al. Among authors: heidel fh. Cell Mol Immunol. 2017 Oct;14(10):805-808. doi: 10.1038/cmi.2017.58. Epub 2017 Jul 10. Cell Mol Immunol. 2017. PMID: 28690329 Free PMC article. No abstract available.

176

Hacking the stem cell niche.

Lane SW, Heidel FH. Lane SW, et al. Among authors: heidel fh. Blood. 2017 Jun 1;129(22):2951-2952. doi: 10.1182/blood-2017-04-777789. Blood. 2017. PMID: 28572172 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

176 results

Search Page

Filters